SMMT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
220.5M
+13.0%
195.2M
-13.2%
224.9M
-4.0%
234.2M
-58.8%
568.4M
R&D
157.7M
+18.9%
132.6M
-10.0%
147.3M
+12.4%
131.1M
-37.0%
208.0M
SG&A
62.8M
+0.3%
62.6M
-19.4%
77.6M
-24.7%
103.1M
-71.4%
360.4M
Operating Income
-220496000
-13.0%
-195212000
+13.2%
-224925000
+4.0%
-234211000
+58.8%
-568437000
EBITDA
-220450000
-13.0%
-195168000
+13.2%
-224883000
+4.0%
-234169000
+58.8%
-568400000
Net Income
-215666000
-13.9%
-189424000
+13.6%
-219172000
+5.4%
-231793000
+59.0%
-565897000
EPS (Basic)
$-0.28
-16.7%
$-0.24
+17.2%
$-0.29
+6.5%
$-0.31
+59.2%
$-0.76
EPS (Diluted)
$-0.28
-16.7%
$-0.24
+17.2%
$-0.29
+6.5%
$-0.31
+59.2%
$-0.76
Shares (Diluted)
778.2M
+0.4%
775.5M
+1.1%
766.7M
+3.1%
743.4M
+0.1%
742.6M
Summit Therapeutics (SMMT) โ€” Financials